| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 1.211 +56.81% on 02/11/26 | | 2.300 -17.43% on 02/12/26 | -0.201 (-9.57%) since 02/10/26 |
| 3-Month | 1.211 +56.81% on 02/11/26 | | 2.500 -24.04% on 02/05/26 | +0.079 (+4.34%) since 12/10/25 |
| 52-Week | 0.550 +245.27% on 08/21/25 | | 2.700 -29.67% on 10/20/25 | +0.224 (+13.37%) since 03/10/25 |
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC...
Genflow Biosciences Signs MSA with Heureka Labs, Launching AI-Powered Partnership in Gene Therapy Research
Genflow Biosciences Launches New Ophthalmology Development Program
LONDON, UNITED KINGDOM / ACCESS Newswire / March 28, 2025 / 1. Issuer Details
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC...
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC...
LONDON, UK / ACCESS Newswire / February 20, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing...
TR-1: Standard form for notification of major holdings
TR-1: Standard form for notification of major holdings
Genflow Biosciences Plc
| 3rd Resistance Point | 2.050 |
| 2nd Resistance Point | 1.975 |
| 1st Resistance Point | 1.900 |
| Last Price | 1.899 |
| 1st Support Level | 1.750 |
| 2nd Support Level | 1.675 |
| 3rd Support Level | 1.600 |
| 52-Week High | 2.700 |
| Last Price | 1.899 |
| Fibonacci 61.8% | 1.879 |
| Fibonacci 50% | 1.625 |
| Fibonacci 38.2% | 1.371 |
| 52-Week Low | 0.550 |